След перорално приложение Cmax на ривастигмин е приблизително 60% по- висока и
After oral administration, the Cmax of rivastigmine was approximately 60% higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects.